Literature DB >> 23784375

Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle.

Nikolai Klymiuk1, Andreas Blutke, Alexander Graf, Sabine Krause, Katinka Burkhardt, Annegret Wuensch, Stefan Krebs, Barbara Kessler, Valeri Zakhartchenko, Mayuko Kurome, Elisabeth Kemter, Hiroshi Nagashima, Benedikt Schoser, Nadja Herbach, Helmut Blum, Rüdiger Wanke, Annemieke Aartsma-Rus, Christian Thirion, Hanns Lochmüller, Maggie C Walter, Eckhard Wolf.   

Abstract

Duchenne muscular dystrophy (DMD) is caused by mutations in the X-linked dystrophin (DMD) gene. The absence of dystrophin protein leads to progressive muscle weakness and wasting, disability and death. To establish a tailored large animal model of DMD, we deleted DMD exon 52 in male pig cells by gene targeting and generated offspring by nuclear transfer. DMD pigs exhibit absence of dystrophin in skeletal muscles, increased serum creatine kinase levels, progressive dystrophic changes of skeletal muscles, impaired mobility, muscle weakness and a maximum life span of 3 months due to respiratory impairment. Unlike human DMD patients, some DMD pigs die shortly after birth. To address the accelerated development of muscular dystrophy in DMD pigs when compared with human patients, we performed a genome-wide transcriptome study of biceps femoris muscle specimens from 2-day-old and 3-month-old DMD and age-matched wild-type pigs. The transcriptome changes in 3-month-old DMD pigs were in good concordance with gene expression profiles in human DMD, reflecting the processes of degeneration, regeneration, inflammation, fibrosis and impaired metabolic activity. In contrast, the transcriptome profile of 2-day-old DMD pigs showed similarities with transcriptome changes induced by acute exercise muscle injury. Our studies provide new insights into early changes associated with dystrophin deficiency in a clinically severe animal model of DMD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23784375     DOI: 10.1093/hmg/ddt287

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  61 in total

Review 1.  Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Authors:  Versha Prakash; Marc Moore; Rafael J Yáñez-Muñoz
Journal:  Mol Ther       Date:  2016-01-14       Impact factor: 11.454

Review 2.  Genetically engineered livestock for biomedical models.

Authors:  Christopher S Rogers
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

3.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

Review 4.  Porcine models of muscular dystrophy.

Authors:  Joshua T Selsby; Jason W Ross; Dan Nonneman; Katrin Hollinger
Journal:  ILAR J       Date:  2015

Review 5.  Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.

Authors:  Nalinda B Wasala; Shi-Jie Chen; Dongsheng Duan
Journal:  Expert Opin Drug Discov       Date:  2020-01-30       Impact factor: 6.098

6.  Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.

Authors:  David K Meyerholz; Georgina K Ofori-Amanfo; Mariah R Leidinger; J Adam Goeken; Rajesh Khanna; Jessica C Sieren; Benjamin W Darbro; Dawn E Quelle; Jill M Weimer
Journal:  J Histochem Cytochem       Date:  2017-08-28       Impact factor: 2.479

Review 7.  Dystrophin-deficient large animal models: translational research and exon skipping.

Authors:  Xinran Yu; Bo Bao; Yusuke Echigoya; Toshifumi Yokota
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

9.  Direct introduction of gene constructs into the pronucleus-like structure of cloned embryos: a new strategy for the generation of genetically modified pigs.

Authors:  Mayuko Kurome; Simon Leuchs; Barbara Kessler; Elisabeth Kemter; Eva-Maria Jemiller; Beatrix Foerster; Nikolai Klymiuk; Valeri Zakhartchenko; Eckhard Wolf
Journal:  Transgenic Res       Date:  2016-12-10       Impact factor: 2.788

Review 10.  Genetically modified pigs to model human diseases.

Authors:  Tatiana Flisikowska; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2014-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.